Overview

An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)

Status:
Completed
Trial end date:
2013-08-31
Target enrollment:
0
Participant gender:
All
Summary
This is an observational study to compare the effectiveness of dual therapy of Type II diabetes mellitus with metformin + sitagliptin versus metformin + a sulfonylurea in routine clinical practice in France.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Hypoglycemic Agents
Metformin
Sitagliptin Phosphate
Criteria
Inclusion Criteria:

- Type 2 diabetes participants

- De novo treatment (first prescription or dated within the past 8 weeks) with:

- Metformin + sitagliptin dual therapy,

- Metformin + sulfonylurea dual therapy,

- Sitagliptin as part of another treatment regimen

- Participants also eligible for treatment with sitagliptin (Januvia®/Xelevia®) or a
sulfonylurea.